Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
In its results for the six months ended 30 September 2019, Mediclinic International announced a 9% growth in revenue.
The company also declared an interim dividend maintained at 3.20p per share.
Adjusted EBITDA was up 4% at £222m, while adjusted earnings per share were flat at 10.3p.
According to the half year report, adjusted operating profit remained flat at £137m, reflecting increased depreciation charges associated with infrastructure and technology investments.
Reported operating profit rose 264% to £142m, reflecting prior year period non-cash Hirslanden impairment charges of £98m